Filing identity and period
Important name mismatch: The supplied filing is BioSig Technologies, Inc.’s Form 10-K for the fiscal year ended December 31, 2014; it does not identify Streamex Corp. as the registrant. Confirm that this is the intended filing. The filing is an annual report, not a standalone fourth-quarter report.
Business context
BioSig is a development-stage medical-device company developing the PURE EP System, intended to acquire and process cardiac signals during electrophysiology studies and ablation procedures. It had no commercial product, customers, or revenue as of the filing, and reported no revenue for 2014 or 2013.
Financial results and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $7.87 million | $6.24 million |
| Operating loss | $7.87 million | $6.24 million |
| Net loss | $8.47 million | $9.80 million |
| Net loss available to common stockholders | $8.77 million | $10.10 million |
| Operating cash used | $2.00 million | $1.76 million |
| Cash at year-end | $239,781 | $302,187 |
Gross margin and other revenue-based margins are not meaningful because the company had no revenue. R&D expense fell 45% to $547,996, while general and administrative expense rose 49% to $7.30 million. The net loss available to common stockholders narrowed 13%, primarily because financing costs declined substantially; operating loss nevertheless increased. FY 2014 stock-based compensation was approximately $5.74 million.
At December 31, 2014, working capital deficit was $910,082; total assets were $353,338, current liabilities were $1.23 million, and stockholders’ deficit was $3.58 million. The balance sheet included $2.71 million of Series C convertible preferred stock, classified outside equity. The company reported no convertible debentures outstanding. The filing does not provide a conventional debt balance that captures the potential preferred-stock redemption exposure.
Operating cash use was funded principally by $1.97 million of common-stock proceeds; financing cash flow was $1.94 million after related-party advance repayments. Cash fell by $62,406 during the year.
Material changes and financing
- Series A and B preferred shares were converted into common stock in June 2014; Series C shares and accrued dividends were also partly converted. Common shares outstanding increased from 8.41 million at year-end 2013 to 11.18 million at year-end 2014.
- In December 2014, the company began a private placement completed in multiple closings through February 10, 2015. It reported aggregate gross proceeds of $2.43 million, alongside common shares and warrants; placement-agent cash fees were $291,072. Additional equity financing increases potential dilution.
- The auditor and management cited substantial doubt about the company’s ability to continue as a going concern. Management estimated year-end cash would not fund the next 12 months and said approximately $2 million in additional funding was needed for that period. The filing also said cash on hand as of February 12, 2015 was approximately $1.41 million and estimated it would cover about five months of projected operating needs.
Outlook, risks, and unusual items
- Management expected prototype validation testing to finish in Q1 2015, targeted an initial Mayo Clinic animal study for April 2015, and estimated FDA 510(k) clearance and potential commercialization in the first half of 2016. These are targets, not assurances, and depend on financing, testing, and regulatory outcomes.
- The company stated that PURE EP test results had not received independent third-party review or peer review. It had not completed formal preclinical testing or human clinical trials described as necessary to establish clinical value.
- Series C preferred stock carries a 9% annual dividend, possible increase to 18% upon specified covenant failures, anti-dilution provisions, and potential redemption obligations upon triggering events. These terms may constrain financing and create cash or dilution risks.
- Development was delayed after a 2013 change in leadership and product strategy; the company later resumed PURE EP development with its original engineering team. A former CEO’s arbitration claim was settled for $100,000; $66,667 remained outstanding at year-end. The filing says there was no outstanding litigation at December 31, 2014.
- Other key risks include inability to complete product development or obtain FDA clearance, competition from larger device companies, reliance on additional funding and outside research collaborators, limited patent protection, and thin OTC trading. The company reported no off-balance-sheet arrangements.
Key facts investors should verify
- Whether BioSig—not Streamex—is the intended issuer and whether the annual period is the intended reporting period.
- Actual cash availability after the reported private-placement closings, placement fees, and subsequent operating expenditures; reconcile the financing amounts and dates.
- Current cash runway, expected funding needs, and the status and terms of any financing raised after the filing date.
- Current Series C preferred-stock balances, dividend and redemption exposure, conversion terms, and fully diluted share count, including warrants and options.
- Progress and independent validation of prototype testing, animal and human studies, and FDA 510(k) plans and timing.
- Status of intellectual-property ownership and protection, including the former CEO dispute and pending patent applications.